Today: 7 February 2026
Subscribe
Browse Category

NYSE:NVO News 14 January 2026 - 25 January 2026

Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

New York, Jan 25, 2026, 13:19 ET — Market closed Healthcare stocks finished last week lower, with XLV — the ETF tracking major U.S. healthcare companies — slipping 0.5% by Friday’s close. Eli Lilly weighed on the sector, though some of the bigger names in the index managed to hold up. The drop followed a choppy week for the broader U.S. market, rattled by earnings reports and geopolitical tensions. Investors were quick to unwind crowded bets. “We’re feeling pretty good, but mindful we might have some significant twists and turns,” said Jason Blackwell, chief investment strategist at Focus Partners Wealth.
25 January 2026
········
Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week

Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week

New York, Jan 24, 2026, 10:05 EST — Market closed Eli Lilly and Co shares fell on Friday, breaking a brief streak of gains as investors refocused on the ongoing battle in the obesity drug sector that has driven the stock’s recent volatility. The shares closed 2.12% lower at $1,064.29. (Investing.com) The decline is significant since Lilly’s valuation hinges largely on its diabetes and weight-loss business, along with its ability to expand access without sacrificing too much on pricing. New data from competitors quickly gets factored into models — and shifts positioning accordingly. U.S. markets are closed for the weekend,
24 January 2026
·····
Eli Lilly stock slips after hours as obesity-pill race stays in the spotlight

Eli Lilly stock slips after hours as obesity-pill race stays in the spotlight

New York, Jan 23, 2026, 18:35 EST — After hours. Eli Lilly and Company (LLY.N) shares dropped 2.1% on Friday, closing near $1,064.29 in after-hours trading. During the session, the stock swung between $1,094.57 and $1,063.25. The pullback comes as investors weigh whether weight-loss pills can expand a market so far dominated by injections. Novo Nordisk’s Wegovy tablet — a GLP-1 drug that suppresses appetite — recorded 18,410 U.S. prescriptions in the week ending Jan. 16, according to IQVIA data cited by analysts. Barclays’ James Gordon described the early tally as “very strong.” Jefferies’ Akash Tewari called the figures “directionally
24 January 2026
·····
Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

New York, Jan 23, 2026, 11:35 ET — Regular session Eli Lilly shares dropped Friday, rattled by investor concerns after rival Novo Nordisk’s Wegovy pill recorded over 18,000 U.S. prescriptions in its first full week on shelves. (Reuters) This read-through is crucial: weight-loss drugs now account for a rising chunk of big pharma’s market value, and the fight is shifting to pills. Prescription data acts almost like a real-time scoreboard, as companies race past injections toward simpler, needle-free treatments. (Reuters) The move comes just two weeks ahead of Lilly’s earnings report, a key moment when any clues on demand, supply,
23 January 2026
······
Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

New York, January 23, 2026, 05:29 EST — Premarket Novo Nordisk A/S (NVO) shares jumped 4.9% to $62.23 in premarket trading Friday following new data revealing a strong surge in U.S. prescriptions for its Wegovy weight-loss drug. The stock closed Thursday at $59.32. The numbers matter because investors now use weekly prescription data as a near-real-time indicator of demand for new obesity drugs, well ahead of quarterly sales reports. Novo is fighting to hold its ground in the GLP-1 drug space — medications that suppress appetite and regulate blood sugar — as competitors ramp up their efforts. The market, meanwhile,
23 January 2026
·····
Novo Nordisk stock rebounds after a bruising drop as investors turn to the next catalyst

Novo Nordisk stock rebounds after a bruising drop as investors turn to the next catalyst

COPENHAGEN, Jan 22, 2026, 13:34 CET — Regular session Novo Nordisk shares rose 4.3% to 389.95 Danish crowns by 1318 CET on Thursday, recovering most of a steep slide the day before. (google.com) The move comes after a volatile run in Copenhagen, with the stock falling about 4% on Wednesday after a 3% rise the previous session, data showed. (investing.com) Investors have been weighing a new long-dated bet in diabetes alongside the nearer-term earnings picture that still hinges on its blockbuster diabetes and obesity medicines. Novo and Canada’s privately held Aspect Biosystems said this week they had struck a partnership
22 January 2026
·····
Novo Nordisk Class B stock jumps — Wegovy pill scripts and UK dose nod set up the week ahead

Novo Nordisk Class B stock jumps — Wegovy pill scripts and UK dose nod set up the week ahead

COPENHAGEN, Jan 18, 2026, 21:16 CET — Market closed. Novo Nordisk A/S Class B shares (NOVOb.CO) surged 6.49% on Friday, closing at 388.9 Danish crowns after hitting a high of 391.3 crowns during the session. The stock is set to reopen Monday, with traders reacting to the latest Wegovy news. (Investing.com) Investors are weighing whether Novo’s once-daily Wegovy pill is gaining traction in the U.S. as the obesity drug market shifts toward a consumer-driven, cash-pay model. IQVIA data revealed 3,071 retail prescriptions filled within the first four days after its Jan. 5 launch. Novo described the “early signs” as positive
18 January 2026
·······
Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Copenhagen, Jan 18, 2026, 13:52 CET — Market closed. Shares of Novo Nordisk jumped 6.49% to 388.90 Danish crowns on Friday, marking their biggest daily gain in weeks. The surge came after new demand signals for its Wegovy obesity drug and a UK approval for a higher Wegovy dose brought the stock back into focus for investors. (MarketWatch) This stock move is significant as investors seek solid proof that Novo can expand Wegovy beyond injections and compete with Eli Lilly in the fiercely contested obesity drug market, a key growth battleground. Markets were closed over the weekend, so Monday will
18 January 2026
····
Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

NEW YORK, January 17, 2026, 14:16 EST — The market has closed. U.S. healthcare stocks wrapped up the week as the S&P 500’s weakest sector, with the Health Care Select Sector SPDR Fund (XLV) slipping 0.8% on Friday to $155.74. Anthony Saglimbene, chief market strategist at Ameriprise Financial, noted that “most investors will take that as a win,” given the market hovered near record highs despite a volatile week. (Reuters) U.S. markets are closed Monday for Martin Luther King Jr. Day, giving healthcare investors an extended break before action resumes Tuesday. The sector has fallen behind despite earnings season picking
17 January 2026
··········
Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Copenhagen, Jan 17, 2026, 10:59 CET — Market closed. Novo Nordisk shares gained 6.5% on Friday, closing at 388.9 Danish crowns, positioning the stock for a notable open Monday. In New York, the company’s ADRs jumped 9.1% to finish at $62.33. (Investing.com) This move is crucial as investors seek confirmation that Novo’s new Wegovy pill will maintain its first-to-market advantage amid growing competition, notably from Eli Lilly’s oral obesity drug. Novo described the “early signs” as positive but cautioned that it’s too soon to draw conclusions about trends for the daily pill. (Reuters) The initial figure was modest but clear:
17 January 2026
·······
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

New York, Jan 15, 2026, 11:16 EST — Regular session. Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock. The stock has struggled to find a clear driver since Pfizer warned in December that 2026 would likely start “bumpy,” with lower COVID-related sales, price cuts tied to a U.S. government deal and key patent expirations looming. Loss of exclusivity is shorthand for patents ending, which can open the door to cheaper rivals. (Reuters) The political noise around vaccines is back in focus. Sanofi Chief Executive Paul
15 January 2026
·········
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

New York, January 14, 2026, 13:46 EST — Regular session Shares of Structure Therapeutics (GPCR) jumped roughly 7.5% Wednesday, as traders returned to small-cap obesity drugmakers. The stock climbed to $83.76, trading over 1 million shares. This shift is crucial as investors wager the weight-loss craze will move from weekly injections to pills, reshaping the buyout landscape. A Novo Nordisk executive told Reuters that oral pills might claim “a third-plus” of the GLP-1 market by 2030. (Reuters) Deal rumors picked up steam on Wednesday after a Bloomberg report, highlighted by TheFly, quoted Novo Nordisk CEO Mike Doustdar saying, “We’re in
14 January 2026
········
1 2 3 4 … 6

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop